Crispr Therapeutics AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham reiterated a Buy rating on the stock and has a $81.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Gil Blum has given his Buy rating due to a combination of factors, primarily centered around the promising data for Crispr Therapeutics AG’s CTX310. The recent results presented at the American Heart Association meeting demonstrated significant dose-dependent reductions in ANGPT3 and triglycerides, indicating the potential efficacy of CTX310 in treating dyslipidemias.
The positive outcomes, which were also published in the New England Journal of Medicine, provide a strong proof-of-concept for CTX310 as a one-time treatment option for dyslipidemia conditions. Additionally, the broad lipid reductions observed across various patient groups, including those with severe hypertriglyceridemia and mixed dyslipidemias, further support the potential impact of this therapy. Crispr’s focus on advancing Phase Ib development for specific dyslipidemia conditions underscores the strategic direction that aligns with these promising results.